Dianthus Therapeutics’ (DNTH) Buy Rating Reiterated at HC Wainwright

Posted by George Bondi on Oct 18th, 2026

HC Wainwright reaffirmed their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a report released on Thursday,Benzinga reports. The firm currently has a $158.00 price target on the stock.

Other research analysts have also recently issued research reports about the company. Truist Financial increased their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wedbush raised their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $131.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Finally, Citigroup assumed coverage on Dianthus Therapeutics in a report on Friday, September 4th. They issued a “buy” rating and a $156.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $129.83.

Get Our Latest Report on Dianthus Therapeutics

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock opened at $72.09 on Thursday. Dianthus Therapeutics has a 1 year low of $32.22 and a 1 year high of $117.88. The firm has a market cap of $3.95 billion, a PE ratio of -17.37 and a beta of 1.35. The company has a 50 day simple moving average of $99.30 and a two-hundred day simple moving average of $94.28.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. The company had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. As a group, research analysts anticipate that Dianthus Therapeutics will post -3.81 earnings per share for the current year.

Insider Activity

In other news, CAO Edward Carr sold 20,000 shares of the company’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $101.38, for a total value of $2,027,600.00. Following the completion of the sale, the chief accounting officer owned 20,000 shares of the company’s stock, valued at approximately $2,027,600. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marino Garcia sold 166,000 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the completion of the sale, the chief executive officer directly owned 65,292 shares of the company’s stock, valued at $7,058,718.12. This trade represents a 71.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 242,429 shares of company stock valued at $26,118,913. Insiders own 3.02% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently added to or reduced their stakes in the business. ABS Investment Management LLC bought a new position in shares of Dianthus Therapeutics during the second quarter valued at about $194,960,000. PNC Financial Services Group Inc. lifted its stake in shares of Dianthus Therapeutics by 0.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after acquiring an additional 139 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Dianthus Therapeutics by 83.6% in the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock valued at $49,000 after acquiring an additional 254 shares during the last quarter. First Horizon Corp purchased a new stake in Dianthus Therapeutics during the 1st quarter valued at about $32,000. Finally, EFG International AG purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at about $49,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

(Get Free Report)

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway.